Placebo-Controlled Trial of Sertraline in the Treatment of Binge Eating Disorder

Publisher Website
Google Scholar
Abstract
The authors' goal was to assess the efficacy of sertraline in the treatment of binge eating disorder. Thirty-four outpatients with DSM-IV binge eating disorder were randomly assigned to receive either sertraline (N=18) or placebo (N=16) in a 6-week, double-blind, flexible-dose (50-200 mg) study. Except for response level, outcome measures were analyzed by random regression methods, with treatment-by-time interaction as the effect measure. Compared with placebo, sertraline was associated with a significantly greater rate of reduction in the frequency of binges, clinical global severity, and body mass index as well as a significantly greater rate of increase in clinical global improvement. Patients receiving sertraline who completed the study demonstrated a higher level of response, although the effect was not significant. In a 6-week trial, sertraline was effective and well tolerated in the treatment of binge eating disorder.

This publication has 4 references indexed in Scilit: